On November 4, 2016, Biocept, Inc. (the
) voluntarily terminated the common stock purchase agreement (the
) that the Company entered into on December 21, 2015, with Aspire Capital Fund, LLC (
).Pursuant to the Purchase Agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Companys common stock over the 30-month term of the Purchase Agreement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized .
Dated: November 4, 2016
/s/ Michael W. Nall
Michael W. Nall
President and Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
General form for registration of securities under the Securities Act of 1933 - Nov. 21, 2017
General form for registration of securities under the Securities Act of 1933 - Nov. 17, 2017
Biocept Reports Third Quarter 2017 Financial Results - Nov. 9, 2017